Alexis A Thompson

List of Publications by Year
in descending order

138 papers	3,265 citations	218677 26 h-index	168389 53 g-index
141 all docs	141 docs citations	141 times ranked	3649 citing authors

#	Article	IF	Citations
1	Gene Therapy in Patients with Transfusion-Dependent Î²-Thalassemia. New England Journal of Medicine, 2018, 378, 1479-1493.	27.0	525
2	Amegakaryocytic thrombocytopenia and radio-ulnar synostosis are associated with HOXA11 mutation. Nature Genetics, 2000, 26, 397-398.	21.4	205
3	A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent Î²-Thalassemia. New England Journal of Medicine, 2020, 382, 1219-1231.	27.0	177
4	Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). Blood, 2014, 124, 2867-2871.	1.4	162
5	Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease. New England Journal of Medicine, 2022, 386, 617-628.	27.0	144
6	Patient-Centered eHealth Interventions for Children, Adolescents, and Adults With Sickle Cell Disease: Systematic Review. Journal of Medical Internet Research, 2018, 20, e10940.	4.3	119
7	Red cell alloimmunization in a diverse population of transfused patients with thalassaemia. British Journal of Haematology, 2011, 153, 121-128.	2.5	108
8	Technology Access and Smartphone App Preferences for Medication Adherence in Adolescents and Young Adults With Sickle Cell Disease. Pediatric Blood and Cancer, 2016, 63, 848-852.	1.5	107
9	Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Blood Advances, 2020, 4, 2058-2063.	5.2	93
10	Betibeglogene Autotemcel Gene Therapy for Nonâ€“Î² ⁰/Î² ⁰ Genotype Î²-Thalassemia. New England Journal of Medicine, 2022, 386, 415-427.	27.0	91
11	Congenital thrombocytopenia and radioâ€ulnar synostosis: a new familial syndrome. British Journal of Haematology, 2001, 113, 866-870.	2.5	86
12	Healthâ€related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease. Pediatric Blood and Cancer, 2017, 64, e26369.	1.5	73
13	Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. Pediatric Blood and Cancer, 2016, 63, 1407-1413.	1.5	70
14	Adherence to hydroxyurea, health-related quality of life domains, and patientsâ€™ perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults. Health and Quality of Life Outcomes, 2017, 15, 136.	2.4	69
15	Medication Adherence and Technology-Based Interventions for Adolescents With Chronic Health Conditions: A Few Key Considerations. JMIR MHealth and UHealth, 2017, 5, e202.	3.7	69
16	Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. Bone, 2008, 43, 162-168.	2.9	64
17	Barriers to hydroxyurea adherence and healthâ€related quality of life in adolescents and young adults with sickle cell disease. European Journal of Haematology, 2017, 98, 608-614.	2.2	62
18	Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. Haematologica, 2019, 104, e51-e53.	3.5	46

#	Article	IF	Citations
19	Beliefs about hydroxyurea in youth with sickle cell disease. Hematology/ Oncology and Stem Cell Therapy, 2018, 11, 142-148.	0.9	43
20	Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study. Haematologica, 2019, 104, 1974-1983.	3.5	43
21	Risk factors for hospitalizations and readmissions among individuals with sickle cell disease: results of a U.S. survey study. Hematology, 2019, 24, 189-198.	1.5	42
22	Interim Results from a Phase 1/2 Clinical Study of Lentiglobin Gene Therapy for Severe Sickle Cell Disease. Blood, 2016, 128, 1176-1176.	1.4	42
23	A systematic review of quality of life in sickle cell disease and thalassemia after stem cell transplant or gene therapy. Blood Advances, 2021, 5, 570-583.	5.2	38
24	Reproductive Health Choices for Young Adults With Sickle Cell Disease or Trait. Nursing Research, 2013, 62, 352-361.	1.7	37
25	Physician decision making in selection of secondâ€line treatments in immune thrombocytopenia in children. American Journal of Hematology, 2018, 93, 882-888.	4.1	30
26	Association between Participantsâ€™ Characteristics, Patient-Reported Outcomes, and Clinical Outcomes in Youth with Sickle Cell Disease. BioMed Research International, 2018, 2018, 1-8.	1.9	29
27	Evaluation of the SCKnowIQ Tool and Reproductive CHOICES Intervention Among Young Adults With Sickle Cell Disease or Sickle Cell Trait. Clinical Nursing Research, 2014, 23, 421-441.	1.6	25
28	Association among sickle cell trait, fitness, and cardiovascular risk factors in CARDIA. Blood, 2017, 129, 723-728.	1.4	24
29	Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2021, 325, 1513.	7.4	24
30	Modifying factors of the health belief model associated with missed clinic appointments among individuals with sickle cell disease. Hematology, 2018, 23, 683-691.	1.5	23
31	Unrelated Donor Transplantation in Children with Thalassemia using Reduced-Intensity Conditioning: The URTH Trial. Biology of Blood and Marrow Transplantation, 2018, 24, 1216-1222.	2.0	23
32	Current Results of Lentiglobin Gene Therapy in Patients with Severe Sickle Cell Disease Treated Under a Refined Protocol in the Phase 1 Hgb-206 Study. Blood, 2018, 132, 1026-1026.	1.4	23
33	Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia. British Journal of Haematology, 2015, 169, 887-898.	2.5	22
34	Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multiâ€center ‹scp›HGB‹/scp›â€206 trial. American Journal of Hematology, 2020, 95, E239-E242.	4.1	22
35	Symptoms of Anxiety and Depression Among Teens and Adults in the Thalassemia Longitudinal Cohort Study.. Blood, 2009, 114, 555-555.	1.4	20
36	A framework for assessing outcomes from newborn screening: on the road to measuring its promise. Molecular Genetics and Metabolism, 2016, 118, 221-229.	1.1	19

#	Article	IF	Citations
37	TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia. Blood, 2015, 126, 3-3.	1.4	19
38	The acute phase inflammatory response to maximal exercise testing in children and young adults with sickle cell anaemia. British Journal of Haematology, 2015, 171, 854-861.	2.5	17
39	Feasibility and safety of home exercise training in children with sickle cell anemia. Pediatric Blood and Cancer, 2017, 64, e26671.	1.5	17
40	Update of Results from the Northstar Study (HGB-204): A Phase 1/2 Study of Gene Therapy for Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex-Vivo with a Lentiviral Beta AT87Q-Globin Vector (LentiGlobin BB305 Drug Product). Blood, 2015, 126, 201-201.	1.4	17
41	Lentiglobin Gene Therapy for Transfusion-Dependent Î²-Thalassemia: Update from the Northstar Hgb-204 Phase 1/2 Clinical Study. Blood, 2016, 128, 1175-1175.	1.4	17
42	Epidemiologic and clinical characteristics of nontransfusionâ€dependent thalassemia in the United States. Pediatric Blood and Cancer, 2018, 65, e27067.	1.5	15
43	The pyruvate kinase (PK) to hexokinase enzyme activity ratio andÂerythrocyte PK protein level in the diagnosis and phenotype of PK deficiency. British Journal of Haematology, 2021, 192, 1092-1096.	2.5	15
44	Heart Rate Recovery Is Impaired after Maximal Exercise Testing in Children with Sickle Cell Anemia. Journal of Pediatrics, 2015, 166, 389-393.e1.	1.8	13
45	Self-Reported Physical Activity and Exercise Patterns in Children With Sickle Cell Disease. Pediatric Exercise Science, 2017, 29, 388-395.	1.0	13
46	Northstar-2: Updated Safety and Efficacy Analysis of Lentiglobin Gene Therapy in Patients with Transfusion-Dependent Î²-Thalassemia and Non-Î²0/Î²0 Genotypes. Blood, 2019, 134, 3543-3543.	1.4	13
47	Computer and mobile technology interventions to promote medication adherence and disease management in people with thalassemia. The Cochrane Library, 2019, 6, CD012900.	2.8	12
48	Advances in the management of sickle cell disease. Pediatric Blood and Cancer, 2006, 46, 533-539.	1.5	11
49	Initial Results from Study Hgb-206: A Phase 1 Study Evaluating Gene Therapy By Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the Lentiglobin BB305 Lentiviral Vector in Subjects with Severe Sickle Cell Disease. Blood, 2015, 126, 3233-3233.	1.4	11
50	ASH Research Collaborative: a real-world data infrastructure to support real-world evidence development and learning healthcare systems in hematology. Blood Advances, 2021, 5, 5429-5438.	5.2	11
51	Deferasirox (ExjadeÂ®), the Once-Daily Oral Iron Chelator, Demonstrates Safety and Efficacy in Patients with Sickle Cell Disease (SCD): 3.5-Year Follow-up.. Blood, 2008, 112, 1420-1420.	1.4	10
52	Initial Results from the Northstar Study (HGB-204): A Phase 1/2 Study of Gene Therapy for Î²-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with a Lentiviral Î²Î‘-T87Q -Globin Vector (LentiGlobin BB305 Drug Product). Blood, 2014, 124, 549-549.	1.4	10
53	Randomization is not associated with socio-economic and demographic factors in a multi-center clinical trial of children with sickle cell anemia. Pediatric Blood and Cancer, 2014, 61, 1529-1535.	1.5	9
54	Unrelated donor stem cell transplantation for transfusionâ€dependent thalassemia. Annals of the New York Academy of Sciences, 2016, 1368, 122-126.	3.8	9

#	Article	IF	Citations
55	Combination Oral Chelation in Adult Patients With Transfusion-dependent Thalassemia and High Iron Burden. Journal of Pediatric Hematology/Oncology, 2019, 41, e47-e50.	0.6	9
56	Multicenter Investigation Of Unrelated Donor Hematopoietic Cell Transplantation (HCT) For Thalassemia Major After a Reduced Intensity Conditioning Regimen (URTH Trial). Blood, 2013, 122, 543-543.	1.4	9
57	Barriers and facilitators to research participation among adults, and parents of children with sickle cell disease: A transâ€regional survey. American Journal of Hematology, 2016, 91, E461-2.	4.1	8
58	Inâ€flight emergencies: Medical kits are not good enough for kids. Journal of Paediatrics and Child Health, 2016, 52, 363-365.	0.8	8
59	Characterization of the severe phenotype of pyruvate kinase deficiency. American Journal of Hematology, 2020, 95, E281.	4.1	8
60	Comorbid Medical Conditions in Young Athletes: Considerations for Preparticipation Guidance During the COVID-19 Pandemic. Sports Health, 2020, 12, 456-458.	2.7	8
61	Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial. JMIR Research Protocols, 2021, 10, e27650.	1.0	8
62	Time to rethink haemoglobin threshold guidelines in sickle cell disease. British Journal of Haematology, 2021, 195, 518-522.	2.5	7
63	Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy. Blood, 2019, 134, 2061-2061.	1.4	7
64	Favorable Outcomes in Pediatric Patients in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies of Betibeglogene Autotemcel Gene Therapy for the Treatment of Transfusion-Dependent Î²-Thalassemia. Blood, 2020, 136, 52-54.	1.4	7
65	Health-Related Quality of Life Outcomes for Patients with Transfusion-Dependent Beta-Thalassemia Treated with Luspatercept in the Believe Trial. Blood, 2020, 136, 8-9.	1.4	7
66	Toward understanding familyâ€related characteristics of young adults with sickleâ€cell disease or sickleâ€cell trait in the USA. Journal of Clinical Nursing, 2016, 25, 1587-1597.	3.0	6
67	Long-Term Efficacy and Safety of Betibeglogene Autotemcel Gene Therapy for the Treatment of Transfusion-Dependent Î²-Thalassemia: Results in Patients with up to 6 Years of Follow-up. Blood, 2020, 136, 51-52.	1.4	6
68	Genes Influencing the Development and Severity of Chronic ITP Identified through Whole Exome Sequencing. Blood, 2015, 126, 73-73.	1.4	6
69	The Inflammatory Response To Cardiopulmonary Exercise Testing In Children and Young Adults With Sickle Cell Anemia. Blood, 2013, 122, 2242-2242.	1.4	6
70	Consensus statement for the perinatal management of patients with Î± thalassemia major. Blood Advances, 2021, 5, 5636-5639.	5.2	6
71	Primary Prophylaxis in Sickle Cell Disease: Is It Feasible? Is It Effective?. Hematology American Society of Hematology Education Program, 2011, 2011, 434-439.	2.5	5
72	Management of Thalassemias. , 2016, , 39-51.		5

#	Article	IF	Citations
73	Parvovirus B19 infection in sickle cell disease: An analysis from the Centers for Disease Control haemoglobinopathy blood surveillance project. Transfusion Medicine, 2020, 30, 226-230.	1.1	5
74	Improvements in Health-Related Quality of Life for Patients Treated with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy. Blood, 2020, 136, 10-10.	1.4	5
75	Long-Term Efficacy and Safety of Deferasirox (ExjadeÂ®, ICL670), a Once-Daily Oral Iron Chelator, in Patients with Sickle Cell Disease (SCD).. Blood, 2007, 110, 3395-3395.	1.4	5
76	Elevated Systolic Blood Pressure and Low Fetal Hemoglobin Are Risk Factors for Silent Cerebral Infarcts in Children with Sickle Cell Anemia.. Blood, 2009, 114, 262-262.	1.4	5
77	Chelation Choices and Iron Burden Among Patients with Thalassemia in the 21st Century: a Report From the Thalassemia Clinical Research Network (TCRN) Longitudinal Cohort.. Blood, 2009, 114, 4056-4056.	1.4	5
78	A patientâ€centered medical home model for comprehensive sickle cell care in infants and young children. Pediatric Blood and Cancer, 2020, 67, e28275.	1.5	4
79	Understanding sickle cell disease: impact of surveillance and gaps in knowledge. Blood Advances, 2020, 4, 496-498.	5.2	4
80	Resolution of Serious Vaso-Occlusive Pain Crises and Reduction in Patient-Reported Pain Intensity: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy. Blood, 2020, 136, 16-17.	1.4	4
81	Deferasirox (ExjadeÂ®) Monotherapy Significantly Reduces Cardiac Iron Burden in Chronically Transfused Î²-Thalassemia Patients: An MRI T2* Study. Blood, 2008, 112, 3882-3882.	1.4	4
82	Molecular Characterization of 140 Patients in the Pyruvate Kinase Deficiency (PKD) Natural History Study (NHS): Report of 20 New Variants. Blood, 2015, 126, 3337-3337.	1.4	4
83	An update on the US adult thalassaemia population: a report from the CDC thalassaemia treatment centres. British Journal of Haematology, 2022, 196, 380-389.	2.5	4
84	Metformin for treatment of cytopenias in children and young adults with Fanconi anemia. Blood Advances, 2022, 6, 3803-3811.	5.2	4
85	Association between hospital admissions and healthcare provider communication for individuals with sickle cell disease. Hematology, 2020, 25, 229-240.	1.5	3
86	Does Gene Therapy in Beta Thalassemia Normalize Novel Markers of Ineffective Erythropoiesis and Iron Homeostasis?. Blood, 2019, 134, 816-816.	1.4	3
87	Pulmonary Hypertension in Thalassemia Assessed by Echocardiography: A Report From Baseline Data of the Thalassemia Clinical Research Network Longitudinal Cohort Study.. Blood, 2009, 114, 2016-2016.	1.4	3
88	Polyclonality Strongly Correlates with Biological Outcomes and Is Significantly Increased Following Improvements to the Phase 1/2 HGB-206 Protocol and Manufacturing of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy (GT). Blood, 2021, 138, 561-561.	1.4	3
89	Concordance with comprehensive iron assessment, hepatitis A vaccination, and hepatitis B vaccination recommendations among patients with sickle cell disease and thalassaemia receiving chronic transfusions: an analysis from the Centers for Disease Control haemoglobinopathy blood safety project. British Journal of Haematology, 2021, 195, e160-e164.	2.5	2
90	Red Blood Cell Allo and Autoantibody Production in Patients in the Thalassemia Clinical Research Network.. Blood, 2005, 106, 1890-1890.	1.4	2

#	Article	IF	Citations
91	Refining Th Predictive Value of Secretory Phospholipase A2 In Sickle Cell Disease Patients with Acute Chest Syndrome. Blood, 2010, 116, 846-846.	1.4	2
92	Sildenafil Therapy in Patients with Thalassemia and an Elevated Tricuspid Regurgitant Jet Velocity (TRV) On Doppler Echocardiography At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network. Blood, 2012, 120, 1023-1023.	1.4	2
93	Habitual Physical Activity and Exercise Patterns in Children and Adolescents with Sickle Cell Disease. Blood, 2014, 124, 4099-4099.	1.4	2
94	Tricuspid Regurgitant Jet Velocity Is Significantly Associated with Hemolysis in the Evaluation of Pulmonary Hypertension in Children and Young Adults with Sickle Cell Disease.. Blood, 2006, 108, 1211-1211.	1.4	2
95	Reliability of Tricuspid Regurgitant Jet Velocity Measurements in Children and Young Adults with Sickle Cell Disease.. Blood, 2009, 114, 2581-2581.	1.4	2
96	Clinical phenotypes of three children with sickle cell disease caused by <scp>HbS</scp>/Sicilian (Î²)⁰â€thalassemia deletion. American Journal of Hematology, 2022, 97, .	4.1	2
97	New developments in the management of sickle cell disease. Blood Advances, 2016, 1, 3-3.	5.2	1
98	Making a case for more sickle cell initiatives in Africa. Blood, 2017, 129, 136-137.	1.4	1
99	A Targeted Agent for Sickle Cell Disease â€" Changing the Protein but Not the Gene. New England Journal of Medicine, 2019, 381, 579-580.	27.0	1
100	HOXA11 Mutation in Amegakaryocytic Thrombocytopenia with Radio-Ulnar Synostosis Syndrome Inhibits Megakaryocytic Differentiation In Vitro.. Blood, 2005, 106, 1751-1751.	1.4	1
101	Serum Ferritin Predicts Liver but Not Cardiac Iron Burden by Noninvasive MRI in Sickle Cell Disease		

#	Article	IF	Citations
109	Changes In Health Status and Quality of Life In Adults with Thalassemia: Year 1 Report of the Thalassemia Longitudinal Cohort Study.. Blood, 2010, 116, 1533-1533.	1.4	1
110	Radioulnar Synostosis and Its Hematology and Genetic Associations. Blood, 2010, 116, 2521-2521.	1.4	1
111	Cardiopulmonary and Laboratory Profiling of Patients with Thalassemia At Risk for Pulmonary Hypertension: Report From the Thalassemia Clinical Research Network.. Blood, 2012, 120, 2122-2122.	1.4	1
112	The Phenotypic Spectrum of Pyruvate Kinase Deficiency (PKD) from the PKD Natural History Study (NHS): Description of Four Severity Groups By Anemia Status. Blood, 2015, 126, 2136-2136.	1.4	1
113	Health Related Quality of Life and Fatigue in Patients with Pyruvate Kinase Deficiency. Blood, 2018, 132, 4807-4807.	1.4	1
114	Pyruvate Kinase (PK) Protein and Enzyme Levels in the Diagnosis and Clinical Phenotype of PK Deficiency. Blood, 2019, 134, 3515-3515.	1.4	1
115	Metformin for Treatment of Cytopenias in Children and Young Adults with Fanconi Anemia. Blood, 2021, 138, 1102-1102.	1.4	1
116	Response of Patients with Transfusion-Dependent Î²-Thalassemia (TDT) to Betibeglogene Autotemcel (beti-cel; LentiGlobin for Î²-Thalassemia) Gene Therapy Based on HBB Genotype and Disease Genetic Modifiers. Blood, 2020, 136, 1-3.	1.4	1
117	Serum Ferritin and Liver Iron Burden by MRI Predict Cardiac Iron Overload in Thalassemia Major.. Blood, 2006, 108, 1771-1771.	1.4	0
118	Acute Chest Syndrome Is Associated with History of Asthma in Hemoglobin SC Disease. Blood, 2008, 112, 2485-2485.	1.4	0
119	Quality of Life in Adolescents and Adults with Thalassemia: A Report of the Thalassemia Longitudinal Cohort.. Blood, 2009, 114, 556-556.	1.4	0
120	Response to Steroids Predicts Response to Rituximab In Pediatric Chronic Immune Thrombocytopenia.. Blood, 2010, 116, 3681-3681.	1.4	0
121	A Comparison of Two Pain Assessment Tools, the Adolescent Pediatric Pain Tool and PAINReportIt and Use of the Composite Pain Index in Sickle Cell Disease. Blood, 2010, 116, 2648-2648.	1.4	0
122	Changes In Health Status and Quality of Life In Parental Reports of Children with Thalassemia: Year 1 Report of the Thalassemia Longitudinal Cohort Study. Blood, 2010, 116, 257-257.	1.4	0
123	The North American Chronic Immune Thrombocytopenia Registry (NACIR): Demographics and Treatment Responses. Blood, 2010, 116, 2509-2509.	1.4	0
124	Division (I): ASH Opposes NCAA Requirement for Screening. , 2012, 9, .		0
125	Heart Rate Recovery Is Impaired After Maximal Exercise Challenge in Pediatric Sickle Cell Anemia. Blood, 2012, 120, 3220-3220.	1.4	0
126	Health-related Smartphone Apps: Status Update for Hem-Onc Practitioners. , 2015, 12, .		0

#	Article	IF	Citations
127	Neither Factor VIII Nor the Putative F8B Protein Is Detectable in Human Peripheral Blood Mononuclear Cells. Blood, 2015, 126, 3507-3507.	1.4	0
128	In a Global State of Mind. , 2018, 15, .		0
129	Hematology's Red Carpet for Innovation. , 2018, 15, .		0
130	ASH: A Year in Review. , 2018, 15, .		0
131	Seizing the Moment for Sickle Cell Disease. , 2018, 15, .		0
132	Characterization of the Severe Phenotype of Pyruvate Kinase Deficiency. Blood, 2019, 134, 949-949.	1.4	0
133	Comorbidities and Complications in Adults with Pyruvate Kinase Deficiency. Blood, 2019, 134, 2175-2175.	1.4	0
134	Clinical Practice Patterns for Hydroxyurea Initiation in Young Children with Sickle Cell Disease. Blood, 2019, 134, 4713-4713.	1.4	0
135	Computer and mobile technology interventions to promote medication adherence and disease management in people with thalassemia. Cochrane Database of Systematic Reviews, 2017, 2017, .	0.5	0
136	Rurioctocog Alfa Pegol Use in Immune Tolerance Induction: Interim Results from an Open-Label Multicenter Clinical Trial in Previously Untreated Patients with Severe Hemophilia a. Blood, 2021, 138, 3185-3185.	1.4	0
137	Addressing Recruitment Challenges in the Engage-HU Trial in Young Children with Sickle Cell Disease. Blood, 2020, 136, 26-27.	1.4	0
138	In Remembrance: Dr. Kwaku Ohene-Frempong. , 2022, 19, .		0